AbCellera (Nasdaq: ABCL) and Versant Ventures today announced a
multi-year collaboration to discover therapeutic antibodies for
multiple targets selected by Versant’s portfolio of
biologics-focused biotechs. Versant and AbCellera already have
enabled three of the firm’s stealth-stage companies under previous
partnerships.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220722005487/en/
Under the terms of the deal, Versant portfolio companies will
have rights to develop and commercialize the resulting therapeutic
antibodies. AbCellera will receive research payments from the
companies and will be eligible to receive downstream clinical and
commercial milestone payments plus royalties on net sales of
products. Further terms are not disclosed.
"In recent years we have made a series of investments into the
next generation of therapeutic antibodies,” said Markus
Enzelberger, Ph.D., a partner at Versant. “We are seeing a wave of
innovation in the antibody space that is allowing us to add novel
functionalities to these molecules. Our partnership with AbCellera
will further enable our portfolio companies to pursue these
important biologic medicines.”
“AbCellera’s discovery technology provides a complete solution
for antibody therapeutics that unlocks new opportunities and levels
the playing field for smaller companies, allowing them to advance
programs faster, more efficiently and with a competitive
advantage,” said Carl Hansen, Ph.D., CEO and President of
AbCellera. “We are excited to deepen our relationship with the
Versant team and look forward to helping them continue a strong
track record of bringing together breakthrough science, experienced
teams, and capital to create bold new biotech companies.”
Previously, Versant and AbCellera partnered in separate
multi-target deals to enable three of the firm’s stealth-stage
companies with new approaches to optimize and expand antibody
therapies. These include antibody-focused newcos in the fields of
immunology and oncology based in Canada, the U.S. and Europe.
About Versant Ventures
Versant Ventures is a leading healthcare venture capital firm
committed to helping exceptional entrepreneurs build the next
generation of great companies. The firm’s emphasis is on
biotechnology companies that are discovering and developing novel
therapeutics. With $4.2 billion under management and offices in the
U.S., Canada and Europe, Versant has built a team with deep
investment, operating and R&D expertise that enables a hands-on
approach to company building. Since the firm’s founding in 1999,
more than 85 Versant companies have achieved successful
acquisitions or IPOs. For more information, please visit
www.versantventures.com.
About AbCellera Biologics Inc.
AbCellera is a technology company that searches, decodes, and
analyzes natural immune systems to find antibodies that its
partners can develop into drugs to prevent and treat disease.
AbCellera partners with drug developers of all sizes, from large
pharmaceutical to small biotechnology companies, empowering them to
move quickly, reduce cost, and tackle the toughest problems in drug
development. For more information, please visit
www.abcellera.com.
AbCellera Forward-looking Statements
This press release contains forward-looking statements,
including statements made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. The
forward-looking statements are based on management’s current
beliefs and assumptions and on information currently available to
management. All statements contained in this release other than
statements of historical fact are forward-looking statements,
including statements regarding our ability to develop,
commercialize and achieve market acceptance of our current and
planned products and services, our research and development
efforts, and other matters regarding our business strategies, use
of capital, results of operations and financial position, and plans
and objectives for future operations.
In some cases, you can identify forward-looking statements by
the words “may,” “will,” “could,” “would,” “should,” “expect,”
“intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,”
“project,” “potential,” “continue,” “ongoing” or the negative of
these terms or other comparable terminology, although not all
forward-looking statements contain these words. These statements
involve risks, uncertainties and other factors that may cause
actual results, levels of activity, performance, or achievements to
be materially different from the information expressed or implied
by these forward-looking statements. These risks, uncertainties and
other factors are described under "Risk Factors," "Management's
Discussion and Analysis of Financial Condition and Results of
Operations" and elsewhere in the documents we file with the
Securities and Exchange Commission from time to time. We caution
you that forward-looking statements are based on a combination of
facts and factors currently known by us and our projections of the
future, about which we cannot be certain. As a result, the
forward-looking statements may not prove to be accurate. The
forward-looking statements in this press release represent our
views as of the date hereof. We undertake no obligation to update
any forward-looking statements for any reason, except as required
by law.
Versant Legal Notices
Versant Ventures provides investment advisory services solely to
privately offered investment funds. Versant Ventures neither
solicits nor makes its services available to the public and none of
the investment funds are currently open to new investors. Please
note that certain statements provided herein may be deemed
forward-looking, but any such statements are not guarantees of any
future performance and actual results or developments may differ
materially from those discussed. The investments identified and
discussed above do not represent all of the investments made or
recommended by Versant. There is no guarantee that any particular
investment will be profitable or that any portfolio company
investments made in the future will equal the performance of the
companies identified herein. Past performance does not guarantee
future results. The information is current as of the date it was
published. The contents are not an offer to sell nor a solicitation
of an offer to purchase interests of Versant or any current or
future related investment fund, nor do they constitute a financial
promotion, investment advice or an inducement or incitement to
participate in any product, offering or investment. An offer
regarding any Versant investment fund may only be made after
receipt of a confidential private placement memorandum, review of
detailed performance information of Versant’s investment funds, and
the opportunity to discuss all matters concerning any prospective
investment in accordance with applicable securities laws.
Source: AbCellera Biologics Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220722005487/en/
AbCellera Media: Jessica Yingling, Ph.D.;
media@abcellera.com, +1(236)521-6774 Business Development: Murray
McCutcheon, Ph.D.; bd@abcellera.com, +1(604)559-9005 Investor
Relations: Melanie Solomon; ir@abcellera.com, +1(778)729-9116
Versant Steve Edelson, VP of investor relations and
communications, sedelson@versantventures.com, +1(415)801-8088
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni AbCellera Biologics (NASDAQ:ABCL)
Storico
Da Lug 2023 a Lug 2024